Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI of Omeprazole and Famotidine on Telotristat Ethyl
NCT03302845Phase 1Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Sep 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telotristat ethyl in Carcinoid Syndrome (CS) (2 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoints: Maximum observed concentration at 7 days, Time of maximum observed concentration at 7 days and 1 more. Started Sep 2017; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT03302845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03302845.